When MBQ-167 was targeted to mammary fatpad tumors established from HER2 overexpressing cells via immunoliposomes functionalized with trastuzumab, MBQ-167 and MBQ-167-loaded liposomes show equal efficacy in reducing the viability of trastuzumab-resistant cells, inhibiting tumor growth in mouse xenografts, and reducing metastasis to lungs and liver. This study demonstrates the efficacy of MBQ-167 as an alternative therapeutic in HER2 overexpressing cancers, delivered either in free form or in liposomes.

almost 2 years ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HER-2 overexpression

Herceptin (trastuzumab) • MBQ-167

almost2years

Implication of Rac1 GTPase in molecular and cellular mitochondrial functions. (PubMed, Life Sci)

Inhibitors of Rac1 have been identified (NSC-23766, EHT-1864) and some are being developed for the treatment of cancer (MBQ-167) or central nervous system diseases (JK-50561). Their effects on mtRac1 warrant further investigations. An overview of mtRac1 is provided here.

almost 2 years ago

Review • Journal

BCL2 (B-cell CLL/lymphoma 2) • RAC1 (Rac Family Small GTPase 1)

NSC23766 • MBQ-167

2years

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer (clinicaltrials.gov)

P1, N=48, Recruiting, MBQ Pharma

2 years ago

New P1 trial • Metastases

MBQ-167

over2years

Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models. (PubMed, Front Oncol)

This was confirmed from splenocytes treated with lipopolysaccharide (LPS) where EHop-016 or MBQ-167 reduced IL-6 secretion in response to LPS. Rac/Cdc42 inhibition induces an antitumor environment via inhibition of both metastatic cancer cells and immunosuppressive myeloid cells in the TME.

over 2 years ago

Preclinical • Journal

IL6 (Interleukin 6)

MBQ-167